Introduction: The incidence of bone metastases increases in direct proportion to the incidence of cancer. Upper extremity metastases are also a serious surgical problem. It is very important to publish experiences on this subject. Method: Treatment results of 80 patients with upper extremity metastases were collected retrospectively. Results: 47 (58.75%) of the patients were male and 33 (41.25%) were female. The most common location for metastasis was the humerus and the most common surgical treatment was intramedullary nailing. Non-surgical treatments were used in 24 (30%) patients. Conclusion: Considering the magnitude of functional losses and the difficulty of surgical options, it is important to collect and evaluate the surgical approaches of upper extremity metastases.
Bone Metastase, Upper Extremity, Humerus Intramedullar Nailin
Birincil Dil | İngilizce |
---|---|
Konular | Sağlık Kurumları Yönetimi |
Bölüm | Clinical Research |
Yazarlar |
|
Erken Görünüm Tarihi | 18 Mart 2022 |
Yayınlanma Tarihi | 18 Mart 2022 |
Gönderilme Tarihi | 30 Ekim 2021 |
Kabul Tarihi | 14 Şubat 2022 |
Yayınlandığı Sayı | Yıl 2022 Cilt: 39 Sayı: 2 |
Bibtex | @araştırma makalesi { omujecm1016578, journal = {Journal of Experimental and Clinical Medicine}, issn = {1309-4483}, eissn = {1309-5129}, address = {}, publisher = {Ondokuz Mayıs Üniversitesi}, year = {2022}, volume = {39}, number = {2}, pages = {449 - 453}, title = {Treatment and outcomes of upper extremity metastases}, key = {cite}, author = {Gürler, Deniz and Gungor, Bedii Safak and Atalay, İsmail Burak and Coşkun, Sina and Büyükceran, İsmail and Şahiner, Göksel} } |
APA | Gürler, D. , Gungor, B. S. , Atalay, İ. B. , Coşkun, S. , Büyükceran, İ. & Şahiner, G. (2022). Treatment and outcomes of upper extremity metastases . Journal of Experimental and Clinical Medicine , 39 (2) , 449-453 . Retrieved from https://dergipark.org.tr/tr/pub/omujecm/issue/68947/1016578 |
MLA | Gürler, D. , Gungor, B. S. , Atalay, İ. B. , Coşkun, S. , Büyükceran, İ. , Şahiner, G. "Treatment and outcomes of upper extremity metastases" . Journal of Experimental and Clinical Medicine 39 (2022 ): 449-453 <https://dergipark.org.tr/tr/pub/omujecm/issue/68947/1016578> |
Chicago | Gürler, D. , Gungor, B. S. , Atalay, İ. B. , Coşkun, S. , Büyükceran, İ. , Şahiner, G. "Treatment and outcomes of upper extremity metastases". Journal of Experimental and Clinical Medicine 39 (2022 ): 449-453 |
RIS | TY - JOUR T1 - Treatment and outcomes of upper extremity metastases AU - DenizGürler, Bedii SafakGungor, İsmail BurakAtalay, SinaCoşkun, İsmailBüyükceran, GökselŞahiner Y1 - 2022 PY - 2022 N1 - DO - T2 - Journal of Experimental and Clinical Medicine JF - Journal JO - JOR SP - 449 EP - 453 VL - 39 IS - 2 SN - 1309-4483-1309-5129 M3 - UR - Y2 - 2022 ER - |
EndNote | %0 Journal of Experimental and Clinical Medicine Treatment and outcomes of upper extremity metastases %A Deniz Gürler , Bedii Safak Gungor , İsmail Burak Atalay , Sina Coşkun , İsmail Büyükceran , Göksel Şahiner %T Treatment and outcomes of upper extremity metastases %D 2022 %J Journal of Experimental and Clinical Medicine %P 1309-4483-1309-5129 %V 39 %N 2 %R %U |
ISNAD | Gürler, Deniz , Gungor, Bedii Safak , Atalay, İsmail Burak , Coşkun, Sina , Büyükceran, İsmail , Şahiner, Göksel . "Treatment and outcomes of upper extremity metastases". Journal of Experimental and Clinical Medicine 39 / 2 (Mart 2022): 449-453 . |
AMA | Gürler D. , Gungor B. S. , Atalay İ. B. , Coşkun S. , Büyükceran İ. , Şahiner G. Treatment and outcomes of upper extremity metastases. J. Exp. Clin. Med.. 2022; 39(2): 449-453. |
Vancouver | Gürler D. , Gungor B. S. , Atalay İ. B. , Coşkun S. , Büyükceran İ. , Şahiner G. Treatment and outcomes of upper extremity metastases. Journal of Experimental and Clinical Medicine. 2022; 39(2): 449-453. |
IEEE | D. Gürler , B. S. Gungor , İ. B. Atalay , S. Coşkun , İ. Büyükceran ve G. Şahiner , "Treatment and outcomes of upper extremity metastases", Journal of Experimental and Clinical Medicine, c. 39, sayı. 2, ss. 449-453, Mar. 2022 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.